[Platinum agent-induced nephrotoxicity via organic cation transport system]

Area of Science:

• Pharmacology
• Nephrology
• Oncology

Background:

• Platinum-based chemotherapy agents share structural similarities and cytotoxic mechanisms.
• Cisplatin is unique among these agents for inducing nephrotoxicity, with its underlying molecular cause remaining elusive.
• Organic cation transporters (OCT/SLC22A) and multidrug and toxin extrusion (MATE/SLC47A) proteins are known to be involved in renal drug handling.

Purpose of the Study:

• To investigate the role of specific transporters in mediating the nephrotoxicity of platinum-based chemotherapy agents.
• To elucidate the molecular mechanisms underlying cisplatin-induced kidney damage.
• To determine if transporter substrate specificity influences the nephrotoxic potential of different platinum agents.

Main Methods:

• Assessing the transport activity of cisplatin, oxaliplatin, carboplatin, and nedaplatin by OCT2 and MATE1/MATE2-K.
• Evaluating the impact of OCT2 and MATE1 on cisplatin-induced nephrotoxicity in experimental models.
• Analyzing the substrate specificity of platinum agents for renal transporters.

Main Results:

• OCT2 was identified as the primary transporter mediating cisplatin uptake and a key determinant of cisplatin-induced nephrotoxicity.
• MATE1 demonstrated a protective role against cisplatin nephrotoxicity.
• Oxaliplatin, a substrate for both OCT2 and MATE2-K, did not exhibit nephrotoxicity, while carboplatin and nedaplatin were not substrates for these transporters.

Conclusions:

• Organic cation transporters play a critical role in regulating the nephrotoxicity of platinum-based chemotherapy drugs.
• The substrate specificity of platinum agents for transporters like OCT2 and MATE family members dictates their potential to cause kidney damage.
• Targeting or understanding these transporter interactions could lead to strategies for mitigating platinum-induced nephrotoxicity.